Efficacy of OxyContin combined with Zoledronic Acid in treatment of advanced breast cancer bone metastasis cancer pain concurrent with chemoradiation therapy
WU Kuo LIU Mengqi ZHAO Qingshu
Department of Radiation Chemotherapy, Jizhong Energy Xingtai Mining Group General Hospital, Hebei Province, Xingtai 054000, China
Abstract：Objective To observe the clinical efficacy of OxyContin combined with Zoledronic Acid in the treatment of advanced breast cancer with bone metastasis cancer pain concurrent with chemoradiation therapy. Methods From April 2017 to April 2018, in Jizhong Energy Xingtai Mining Group General Hospital, 80 patients with advanced breast cancer bone metastasis cancer pain concurrent with chemoradiation therapy were selected, according to random number table method, they were divided into control group and observation group, with 40 cases in each group. Patients in the control group were treated with OxyContin for analgesia, patients in the observation group were treated with OxyContin and Zoledronic Acid for analgesia. The pain level was evaluated by numeric rating scale (NRS), the quality of life of the two groups was evaluated by Karnofsky functional status score (KPS) and the quality of life score (QOL) of the tumor patients, the increase and decrease of OxyContin dosage and adverse reactions in the two groups were observed. Results After 28 days of treatment, the NRS scores of patients in the two groups were lower than before treatment, the KPS score and QOL score were higher than before treatment, the differences were statistically significant (P < 0.05). The NRS scores of patients in the observation group were lower than the control group, the KPS score and QOL score were higher than the control group, the differences were statistically significant (P < 0.05). The rate of OxyContin reduction of patients in the observation group was higher than control group, the difference was statistically significant (P < 0.05). The incidence of constipation of patients in the observation group was lower than control group, the difference was statistically significant (P < 0.05). Conclusion OxyContin combined with Zoledronic Acid has a definite effect in the treatment of advanced breast cancer bone metastasis cancer pain concurrent with chemoradiation therapy. It can effectively reduce the degree of cancer pain, improve the quality of life of patients, and reduce the adverse effects of the simple application of OxyContin, worthy of clinical promotion.
吴阔 刘孟奇 赵庆书. 奥施康定联合唑来膦酸治疗晚期乳腺癌骨转移同期放化疗癌痛的效果[J]. 中国医药导报, 2019, 16(8): 100-103.
WU Kuo LIU Mengqi ZHAO Qingshu. Efficacy of OxyContin combined with Zoledronic Acid in treatment of advanced breast cancer bone metastasis cancer pain concurrent with chemoradiation therapy. 中国医药导报, 2019, 16(8): 100-103.
[1] Group EBCTC. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials [J]. Lancet，2015，386（10001）：1353-1361.
[2] Liede A，Jerzak KJ，Hernandez RK，et al. The incidence of bone metastasis after early-stage breast cancer in Canada [J]. Breast Cancer Restr，2016，156（3）：587-595.
[3] Harries M，Taylor A，Holmberg L，et al. Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients [J]. Cancer Epidemiol，2014， 38（4）：427-434.
[4] Piccioli A，Maccauro G，Spinelli MS，et al. Bone metastases of unknown origin： epidemiology and principles of management [J]. J Orthop Traumatol，2015，16（2）：81-86.
[5] 江泽飞，陈佳艺，牛晓辉，等.乳腺癌骨转移和骨相关疾病临床诊疗专家共识（2014版）[J].中华医学杂志，2015， 95（4）：241-247.
[6] 尚淑平，党勇.奥施康定联合放化疗对晚期乳腺癌患者疼痛治疗的疗效观察[J].实用癌症杂志，2016，31（6）：950-952.
[7] 何玉峰，陈进，鲁光平，等.来曲唑联合唑来膦酸治疗 ER/PR 阳性的绝经后乳腺癌骨转移疗效分析[J].山东医药，2016，56（35）：65-67.
[8] 王如良，江泽飞.乳腺癌骨转移治疗的若干热点问题思考和讨论：乳腺癌骨转移和骨相关疾病临床诊疗专家共识（2014版）解读[J].肿瘤研究与临床，2015，27（10）：707-710.
[9] Hawker G A，Mian S，Kendzerska T，et al. Measures of adult pain： Visual Analog Scale for Pain （VAS Pain），Numeric Rating Scale for Pain （NRS Pain），McGill Pain Questionnaire （MPQ），Short‐Form McGill Pain Questionnaire （SF-MPQ），Chronic Pain Grade Scale （CPGS），Short Form-36 Bodily Pain Scal [J]. Arthrit Care Res，2011，63（S11）：S240-S252.
[10] Mouridsen H，Gershanovich M，Sun Y，et al. Phase Ⅲ study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women：analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group [J]. J Clin Oncol，2016，21（11）：2101-2109.
[11] Farthmann J，Hanjalic-Beck A，Veit J，et al. The impact of chemotherapy for breast cancer on sexual function and health-related quality of life [J]. Support Care Cancer，2016，24（6）：1-7.
[12] 王昆.难治性癌痛专家共识（2017年版）[J].中国肿瘤临床，2017，44（16）：787-793.
[13] 李欣晓，梁仁拔，黄静，等.唑来膦酸联合放疗在恶性肿瘤骨转移治疗中研究进展[J].中华实用诊断与治疗杂志，2018（2）：188-190.
[14] 李泓锡，姚鹏.奥施康定配合射频消融术治疗骨转移癌痛的效果观察[J].实用药物与临床，2017，20（7）：812-815.
[15] 周莲英，徐洋.奥施康定和泰勒宁在晚期癌症中重度疼痛治疗的临床效果分析[J].北方药学，2016，13（12）：52-53.
[16] 戴玉容，郭朝晖.奥施康定联合塞来昔布治疗中重度癌痛的疗效及安全性分析[J].吉林医学，2014（16）：3546-3547.
[17] 郑鸿轩.唑来膦酸联合NP化疗治疗乳腺癌骨转移的效果及2年随访观察[J].临床医学 2016，36（9）：84-86.
[18] 胡群超，俞晓立，郭小毛.放疗在乳腺癌骨转移中的临床应用进展[J].中国癌症杂志，2016，26（4）：346-350.
[19] 陈耀成，廖亚勇，姚金娥，等.奥施康定联合静脉注射吗啡治疗癌痛及爆发痛的临床研究[J].实用肿瘤学杂志，2016，30（5）：436-440.
[20] 廖惠莲.小郁子油子午流注穴位贴敷联合中医护理在预防奥施康定致便秘中的应用[J].护理研究，2016，30（11）：1333-1336.
2019, Vol. 16 
京公网安备 11010502046598号